Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash & Current Investments for 12 consecutive years, with $242.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 62.09% to $242.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $242.8 million, a 62.09% increase, with the full-year FY2025 number at $242.8 million, up 62.09% from a year prior.
  • Cash & Current Investments was $242.8 million for Q4 2025 at ImmunityBio, down from $257.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $317.1 million in Q4 2021 to a low of $46.0 million in Q2 2023.
  • A 5-year average of $152.8 million and a median of $140.1 million in 2024 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: plummeted 66.2% in 2022, then skyrocketed 374.34% in 2024.
  • ImmunityBio's Cash & Current Investments stood at $317.1 million in 2021, then tumbled by 66.2% to $107.2 million in 2022, then surged by 148.6% to $266.5 million in 2023, then tumbled by 43.78% to $149.8 million in 2024, then surged by 62.09% to $242.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Cash & Current Investments are $242.8 million (Q4 2025), $257.8 million (Q3 2025), and $153.7 million (Q2 2025).